Expertise in
27
conditions

Dr. Huong T. Pham

Virginia Mason Medical Center
Seattle, WA
Expertise in
27
conditions
Specialties:Radiation Oncology
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
OverviewInsuranceLocationsClinical Research

Overview

Huong Pham is a Radiation Oncologist in Seattle, Washington. Dr. Pham is highly rated in 27 conditions, according to our data. Her top areas of expertise are Radiation Induced Meningioma, Meningioma, Familial Prostate Cancer, and Posterior Fossa Tumor. Dr. Pham is currently accepting new patients.

Her clinical research consists of participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in WA
Hospital Affiliations
Virginia Mason Medical Center
St Francis Community Hospital
Languages Spoken
English
Spanish
Vietnamese
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  PacificSource
  •  Aetna
  •  Premera
  •  Humana

Locations

VIRGINIA MASON MEDICAL CENTER
925 Seneca St, Seattle, WA 98101
206-223-6600
Other Locations
VIRGINIA MASON MEDICAL CENTER
11800 Ne 128th St, Suite 300, Kirkland, WA 98034
425-814-5100
VIRGINIA MASON MEDICAL CENTER
100 Ne Gilman Blvd, Issaquah, WA 98027
425-557-8000
VIRGINIA MASON MEDICAL CENTER
33501 1st Way S, Federal Way, WA 98003
253-838-2400

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Randomized, Double-Blinded Phase III Study of CABozantinib Versus Placebo IN Patients With Advanced NEuroendocrine Tumors After Progression on Prior Therapy (CABINET)
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Cabozantinib S-malate
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2024
Intervention Type: Radiation
Study Phase: Phase 3
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Radiation
Study Phase: Phase 3
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
Enrollment Status: Completed
Publish Date: May 01, 2024
Intervention Type: Other, Dietary supplement
Study Phase: Phase 2
SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial
SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial
Enrollment Status: Completed
Publish Date: March 25, 2024
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials
Similar Doctors
Upendra Parvathaneni
Expertise in
12
conditions
Dr. Upendra Parvathaneni
Radiation Oncology
Expertise in
12
conditions
Dr. Upendra Parvathaneni
Radiation Oncology

The Association Of University Physicians

1959 Ne Pacific St, 
Seattle, WA 
 (2.9 mi)
206-598-4333
Languages Spoken:
English, Hindi, Tamil, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Upendra Parvathaneni is a Radiation Oncologist in Seattle, Washington. Dr. Parvathaneni is highly rated in 12 conditions, according to our data. His top areas of expertise are Merkel Cell Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Tumors, Olfactory Neuroblastoma, and Gastrostomy. Dr. Parvathaneni is currently accepting new patients.

Expertise in
32
conditions
Dr. Lia M. Halasz
Radiation Oncology
Expertise in
32
conditions
Dr. Lia M. Halasz
Radiation Oncology

The Association Of University Physicians

325 9th Ave, 
Seattle, WA 
 (0.5 mi)
206-731-3000
Languages Spoken:
English, German, Korean, Portuguese, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Lia Halasz is a Radiation Oncologist in Seattle, Washington. Dr. Halasz is highly rated in 32 conditions, according to our data. Her top areas of expertise are Oligodendroglioma, Astrocytoma, Brain Tumor, and Glioblastoma. Dr. Halasz is currently accepting new patients.

Expertise in
23
conditions
Dr. Jason K. Rockhill
Radiation Oncology
Expertise in
23
conditions
Dr. Jason K. Rockhill
Radiation Oncology
University Of Washington Medical Ctr, 1959 Ne Pacific St, 
Seattle, WA 
 (2.8 mi)
206-598-4100
Languages Spoken:
English, French, Japanese
See accepted insurances
Accepting New Patients
Offers Telehealth

Jason Rockhill is a Radiation Oncologist in Seattle, Washington. Dr. Rockhill is highly rated in 23 conditions, according to our data. His top areas of expertise are Glioblastoma, Glioma, Astrocytoma, Meningioma, and Gamma Knife Radiosurgery. Dr. Rockhill is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile